10-K: Longduoduo Reports 57% Revenue Drop, Net Loss

Longduoduo Company Limited's annual report for the fiscal year ended June 30, 2026, reveals a substantial 57% decrease in total revenue to $1.82 million and a net loss of $642,267.

Summary

• Longduoduo Company Limited reported a total revenue of $1,822,457 for the fiscal year ended June 30, 2026, a significant decrease of 57% from $4,262,663 in the prior year.
• The company incurred a net loss of $642,267 for the fiscal year ended June 30, 2026, compared to a net income of $492,260 in the prior year.
• Operating expenses decreased by 33% to $2,438,680, primarily due to reduced advertising and promotion expenses.
• The company's business model heavily relies on commission revenue from a single third-party provider, Inner Mongolia Honghai Health Management Co., Ltd., which accounted for over 99.6% of gross revenue in the fiscal year 2026.
• Cash and cash equivalents stood at $1,588,930 as of June 30, 2026, with working capital at $501,414.
• The company faces significant risks related to its dependence on a single commission source, regulatory challenges in China, and potential impacts of U.S.-China relations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant revenue decline, operational losses, and substantial risks associated with its business model and operating environment in China.

Positives

• The company has a substantial cash reserve of $1,588,930 as of June 30, 2026, providing some liquidity.
• Operating expenses were reduced by 33% to $2,438,680, indicating cost management efforts.
• The company has a plan for growth focused on expanding product offerings, network coverage, and service standards.

Negatives

• Total revenue decreased by 57% to $1,822,457 for the fiscal year ended June 30, 2026.
• The company reported a net loss of $642,267 for the fiscal year ended June 30, 2026, a reversal from a net income of $492,260 in the prior year.
• Service revenue from principal sales fell by almost 95% in the year ended June 30, 2026.
• The company's gross profit margin on service revenue was negative (-159%) due to minimal service revenue and fixed costs.
• The company has significant material weaknesses in its internal controls and disclosure procedures, including lack of segregation of duties and insufficient expertise in U.S. GAAP.
• The company's reliance on a single commission source (Honghai) for over 99.6% of its revenue presents a significant risk.

Risks

• 99.6% of revenue in fiscal year 2026 came from a single source, Inner Mongolia Honghai Health Management Co., Ltd., and termination of this relationship would severely impact financial results.
• Reliance on third-party healthcare providers for services means the company could be liable and suffer reputational harm if these providers deliver inferior service or harm a customer.
• Cybersecurity threats, data breaches, or failures in computer systems could disrupt business, damage reputation, and lead to regulatory and litigation exposure.
• Failure to maintain adequate processes and controls, or non-compliance with laws and regulations, could lead to misappropriation or disclosure of personal or confidential information.
• Intense competition from major public hospitals and private medical companies, some with greater resources, could harm the business.
• The company may not be able to effectively control and manage its planned growth due to limited operational, administrative, and financial resources.
• Expansion of government-sponsored social medical insurance in China could negatively impact the business if the company does not qualify for coverage.
• Additional capital may not be available on acceptable terms, or at all, and any financing may result in dilution or adverse terms for existing shareholders.

Future Outlook

The company plans to improve its operations by adjusting its policies and investing in advertising and promotion to establish and expand its brand and services. However, the outlook is heavily dependent on economic recovery and the continuation of its primary revenue source.

Management Comments

• Management believes that the government has recently introduced policies to promote economic recovery, but it may take some time for the situation to truly improve.
• The Company is implementing plans to improve its operations by adjusting its operational policies.
• The Company will continue to invest heavily in advertising and promotion expenses in the near future as it continues to establish and expand its brand and products and services.
• Management does not believe that the current level of the Companys operations warrants a remediation of the weaknesses identified in its internal controls.

Industry Context

StockSavvy.ai notes that the company operates in the preventive healthcare sector in China, which is subject to evolving regulations and intense competition. The heavy reliance on a single third-party provider for commission revenue is a significant deviation from a more traditional service provider model and highlights a vulnerability.

Comparison to Industry Standards

• The company's revenue decline of 57% is significantly worse than the typical performance of established healthcare service providers in more stable markets.
• The negative gross margin on service revenue (-159%) is highly unusual and indicates a fundamental issue with the principal sales model, contrasting sharply with industry norms where service revenue typically contributes positively to gross profit.
• The heavy reliance on commission revenue from a single partner (99.6% of revenue) is not a standard or sustainable model for a healthcare service company and exposes it to risks far beyond those faced by diversified industry players.
• The material weaknesses in internal controls and disclosure procedures are a significant concern compared to publicly traded companies with robust governance frameworks.

Corporate Governance

Legal Proceedings

• The company is not presently a party to any legal proceedings that, if determined adversely, would individually or taken together have a material adverse effect on its business, operating results, financial condition, or cash flows.

Related Party Transactions

• Advances due to related parties (Zhang Liang and Xu Huibo) are unsecured, repayable on demand, and bear no interest.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional securities, as they do not have pre-emptive rights.
• The company is unlikely to pay cash dividends in the foreseeable future, as earnings are intended for business operations and expansion.
• The majority shareholder, Zhang Liang, holds effective control over the company, impacting decisions on directors, amendments, mergers, and other corporate transactions.
• Employees are located in the PRC and are not represented by a labor union.

Next Steps

• The company plans to continue investing heavily in advertising and promotion expenses to establish and expand its brand and products and services.
• The company will strive to achieve a better balance of customer deposits and prepayments.
• Management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures, as well as its internal control over financial reporting, on an ongoing basis.

Key Dates

Recommendation

The significant revenue decline, shift to a net loss, heavy reliance on a single revenue source, and substantial operational and regulatory risks, particularly those related to doing business in China, present a highly unfavorable investment profile. The material weaknesses in internal controls further exacerbate these concerns, suggesting a high level of risk for investors.

Keywords

healthcare services, commission revenue, China operations, regulatory risk, financial performance, risk factors, operating subsidiaries, preventive healthcare